Literature DB >> 11391504

[Blood neuronal specific enolase in newborns with perinatal asphyxia].

A Verdú Pérez1, M P Falero, A Arroyos, F Estévez, V Félix, Y López, A Pantoja, A Ureta.   

Abstract

INTRODUCTION: Neuron-specific enolase (NSE) is a sensitive marker of brain injury after hypoxia or ischemia. There are few studies about its usefulness in asphyctic newborns.
OBJECTIVE: To study the correlation between blood NSE levels and neurological outcome in newborns with hypoxic ischemic encephalopathy. PATIENTS AND METHODS: We have determined the blood values of NSE by radioimmunoassay in 25 asphyctic term-newborns with clinical encephalopathy (of mild, moderate and severe degree) and in 22 healthy term newborns (control group). Blood samples were obtained between 24 and 72 hours after birth in all neonates. Surviving infants were followed for a variable time (median: 3.5 years; range: 1-6) and the neurological status was determined.
RESULTS: NSE levels in the group of asphyctic neonates who died or developed neurological sequelae (n= 6; mean: 116.4 ng/ml; range: 42-226) were significantly higher than NSE values in the group of asphyctic neonates who were neurologically normal at follow-up (n= 19; mean: 21.3 ng/ml; range: 7.4-40), with p< 0.001. There were not differences between NSE values in the group of asphyctic neonates who developed neurologically normal and the control group (mean: 7.6 ng/ml; range: 10.3-28.3). Sensitivity and specificity of blood NSE as predictor of poor outcome were, respectively, 100% and 78%. The combined specificity for blood NSE together with a moderate/severe encephalopathy was 95%.
CONCLUSIONS: The presence of elevated NSE values in blood after perinatal asphyxia can be a sensitive indicator of conspicuous brain damage. The combined information provided by the severity of the encephalopathy together with the blood NSE values have shown a high predictive value for neurological outcome.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11391504

Source DB:  PubMed          Journal:  Rev Neurol        ISSN: 0210-0010            Impact factor:   0.870


  6 in total

1.  Biomarkers of brain injury in neonatal encephalopathy treated with hypothermia.

Authors:  An N Massaro; Taeun Chang; Nadja Kadom; Tammy Tsuchida; Joseph Scafidi; Penny Glass; Robert McCarter; Stephen Baumgart; Gilbert Vezina; Karin B Nelson
Journal:  J Pediatr       Date:  2012-04-10       Impact factor: 4.406

2.  Umbilical cord blood biomarkers of neurologic injury and the risk of cerebral palsy or infant death.

Authors:  Maged M Costantine; Steven J Weiner; Dwight J Rouse; Deborah G Hirtz; Michael W Varner; Catherine Y Spong; Brian M Mercer; Jay D Iams; Ronald J Wapner; Yoram Sorokin; John M Thorp; Susan M Ramin; Mary J O'Sullivan; Alan M Peaceman; Hyagriv N Simhan
Journal:  Int J Dev Neurosci       Date:  2011-06-25       Impact factor: 2.457

3.  Serum neuron-specific enolase, magnetic resonance imaging, and electrophysiology for predicting neurodevelopmental outcomes of neonates with hypoxic-ischemic encephalopathy: a prospective study.

Authors:  Hui-Zhi Huang; Xiao-Feng Hu; Xiao-Hong Wen; Li-Qi Yang
Journal:  BMC Pediatr       Date:  2022-05-17       Impact factor: 2.567

4.  Umbilical artery blood S100beta protein: a tool for the early identification of neonatal hypoxic-ischemic encephalopathy.

Authors:  Jing Qian; Dong Zhou; Yu-Wei Wang
Journal:  Eur J Pediatr       Date:  2008-04-09       Impact factor: 3.183

5.  Neuroprotection of lamotrigine on hypoxic-ischemic brain damage in neonatal rats: Relations to administration time and doses.

Authors:  Yong-Hong Yi; Wen-Chao Guo; Wei-Wen Sun; Tao Su; Han Lin; Sheng-Qiang Chen; Wen-Yi Deng; Wei Zhou; Wei-Ping Liao
Journal:  Biologics       Date:  2008-06

6.  The association of serum neuron-specific enolase with other disease markers in chronic obstructive pulmonary disease: A case-control study.

Authors:  Jie Li; Xinyi Kong; Wei Shu; Wei Zhang
Journal:  Pak J Med Sci       Date:  2018 Sep-Oct       Impact factor: 1.088

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.